Ibrance (palbociclib) tablets, 25mg (YJ code: 4291051F1022, standard: 25mg 1 tablet), manufactured by Pfizer, are a cyclin-dependent kinase (CDK) 4/6 inhibitor used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is typically used in combination with an aromatase inhibitor or fulvestrant to slow cancer cell growth and spread.
Ibrance tablets 25mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →